Five-year Outcomes of Ranibizumab in Neovascular Age-related Macular Degeneration: Real Life Clinical Experience
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To evaluate the outcomes of 5-year ranibizumab treatment in neovascular age-related macular degeneration(nAMD) in a single center and real life clinical setting. Methods: The records of nAMD patients who were treated with ranibizumab between January 2010 and June2011 were retrospectively reviewed. Patients who completed 5 years of follow-up were included. Main outcomemeasures were change in best-corrected visual acuity, central retinal thickness, and visit and injectionnumbers. Results: Forty-four eyes of 37 patients were included. Mean best-corrected visual acuity decreased from 0.82± 0.69 to 1.11 ± 0.65 logarithm of minimal angle of resolution after 5 years. Twenty-four eyes (54.5%) had visualacuity loss ≥3 lines, and 20 eyes (45.5%) had stable or improved vision (loss <3 lines, remained stable, orgained ≥1 line) at month 60. The mean total number of visits was 25.3 ± 5.8 (range, 14 to 42), and the meantotal number of injections was 12.6 ± 6.4 (range, 3 to 26) at month 60. Conclusions: Half of the ranibizumab-treated nAMD patients maintained their vision during the 5 years of follow-up. Visit and injection numbers were found to be lower than in prospective studies, reflecting a real worldclinical practice.
Abstract
Purpose: To evaluate the outcomes of 5-year ranibizumab treatment in neovascular age-related macular degeneration(nAMD) in a single center and real life clinical setting. Methods: The records of nAMD patients who were treated with ranibizumab between January 2010 and June2011 were retrospectively reviewed. Patients who completed 5 years of follow-up were included. Main outcomemeasures were change in best-corrected visual acuity, central retinal thickness, and visit and injectionnumbers. Results: Forty-four eyes of 37 patients were included. Mean best-corrected visual acuity decreased from 0.82± 0.69 to 1.11 ± 0.65 logarithm of minimal angle of resolution after 5 years. Twenty-four eyes (54.5%) had visualacuity loss ≥3 lines, and 20 eyes (45.5%) had stable or improved vision (loss <3 lines, remained stable, orgained ≥1 line) at month 60. The mean total number of visits was 25.3 ± 5.8 (range, 14 to 42), and the meantotal number of injections was 12.6 ± 6.4 (range, 3 to 26) at month 60. Conclusions: Half of the ranibizumab-treated nAMD patients maintained their vision during the 5 years of follow-up. Visit and injection numbers were found to be lower than in prospective studies, reflecting a real worldclinical practice.
참고문헌 (20)
- Soubrane G, "Occult subretinal new vessels in age-related macular degeneration: natural history and early laser treatment", Ophthalmology, 97, pp.649~657 (1990)
- Roy M, "Second eye involvement in age-related macular degeneration: a four-year prospective study", Eye (Lond), 4(Pt 6), pp.813~818 (1990)
- Kim SH, "ICG-enhanced digital angiography and photocoagulation of choroidal neovascularization in age-related macular degeneration", Korean J Ophthalmol, 9, pp.59~65 (1995)
- Kapran Z, "Hemorrhagic age-related macular degeneration managed with vitrectomy, subretinal injection of tissue plasminogen activator, gas tamponade, and upright positioning", Ophthalmic Surg Lasers Imaging Retina, 44, pp.471~476 (2013)
- 김현웅, "Combined Treatment of Photodynamic Therapy and Bevacizumab for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration", Korean Journal of Ophthalmology, 25(4), pp.231~237 (2011), 대한안과학회
- Rubin GS, "Effects of verteporfin therapy on contrast on sensitivity:results from the treatment of age-related macular degeneration with photodynamic therapy (TAP) investigation-TAP report No 4", Retina, 22, pp.536~544 (2002)
- Dong Kyu Lee, "High Dose Intravitreal Bevacizumab for Refractory Pigment Epithelial Detachment in Age-related Macular Degeneration", Korean Journal of Ophthalmology, 30(4), pp.265~271 (2016), 대한안과학회
- Da Ru Chi Moon, "Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor", Korean Journal of Ophthalmology, 29(4), pp.226~232 (2015), 대한안과학회
- Ozkaya A, "The role of indocyanine green angiography imaging in further differential diagnosis of patients with nAMD who are morphologically poor responders to ranibizumab in a real-life setting", Eye (Lond), 30, pp.958~965 (2016)
- Ozkaya A, "Comparison of intravitreal ranibizumab in phakic and pseudophakic neovascular age-related macular degeneration patients with good baseline visual acuity", Retina, 34, pp.853~859 (2014)
- Brown DM, "Ranibizumab versus verteporfin for neovascular age-related macular degeneration", N Engl J Med, 355, pp.1432~1444 (2006)
- Liu EM, "Intravitreal aflibercept for neovascular AMD: short-term clinical effects of intravitreal aflibercept injection as a predictor of long-term results", Ophthalmic Surg Lasers Imaging Retina, 46, pp.1021~1027 (2015)
- Rosenfeld PJ, "Ranibizumab for neovascular age-related macular degeneration", N Engl J Med, 355, pp.1419~1431 (2006)
- CATT Research Group, "Ranibizumab and bevacizumab for neovascular age-related macular degeneration", N Engl J Med, 364, pp.1897~1908 (2011)
- Rofagha S, "Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP)", Ophthalmology, 120, pp.2292~2299 (2013)
- Cvetkova NP, "Ranibizumab in neovascular age-related macular degeneration: a 5-year follow-up", Clin Ophthalmol, 10, pp.1047~1051 (2016)
- Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, "Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials", Ophthalmology, 123, pp.1751~1761 (2016)
- Ozkaya A, "Is spectral-domain optical coherence tomography essential for flexible treatment regimens with ranibizumab for neovascular age-related macular degeneration?", J Ophthalmol, 2013, pp.786107~ (2013)
- Singer MA, "HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration", Ophthalmology, 119, pp.1175~1183 (2012)
- Holz FG, "Determinants of visual acuity outcomes in eyes with neovascular AMD treated with anti-VEGF agents: an instrumental variable analysis of the AURA study", Eye (Lond), 30, pp.1063~1071 (2016)